What Happened

Century Therapeutics presented preclinical data for CNTY-813, an iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0. The data demonstrated durable glucose control and immune evasion in diabetic mice, aiming to eliminate the need for chronic immunosuppression and exogenous insulin.

Who Is Affected

This development primarily impacts patients with Type 1 Diabetes, healthcare providers, and biotech companies focused on diabetes treatment. The potential for a functional cure could significantly alter treatment protocols and patient outcomes.

Market Impact

• Potential to disrupt the $10 billion Type 1 Diabetes treatment market.
• Increased interest and investment in iPSC-derived therapies.
• Shift in focus towards immune evasion technologies in biotech.

What to Watch

Key milestones include Century Therapeutics' IND submission in Q4 2026 and initial clinical data anticipated in H2 2027. Stakeholders should monitor regulatory approvals and clinical trial outcomes closely.